Core Viewpoint - The technology sector, led by artificial intelligence (AI), is on track for a third consecutive year of over 20% gains, but signs of narrowing leadership and increased volatility are emerging, prompting a shift towards defensive stocks to balance risks in tech holdings [1]. Group 1: Defensive Sectors - Traditional defensive sectors such as blue-chip pharmaceuticals, regulated utilities, and essential consumer goods continue to play a significant role in investment strategies [3]. - Quantitative strategist Steven Cress has identified four high-quality defensive stocks that combine durable cash flows, essential services, and key growth metrics, suitable for investment if the tech sector cools down by 2026 [3]. Group 2: Brookfield Infrastructure (BIP.US) - Brookfield Infrastructure operates a global portfolio of high-quality infrastructure assets, generating predictable cash flows largely insulated from economic cycles, supported by long-term contracts linked to inflation [4]. - The company reported a funds from operations (FFO) of $654 million for Q3 2025, with a per unit FFO of $0.83, reflecting a 9% year-over-year growth [5]. - Brookfield aims to distribute 60-70% of its FFO as dividends, targeting a 5-9% annual dividend growth, making it a foundational holding for defensive allocations in 2026 [5][6]. Group 3: Iberdrola (IBDRY.US) - Iberdrola is one of the largest electric utility companies globally, with a strong focus on renewable energy and regulated pricing structures that provide profit visibility [7]. - The company reported a 16.6% year-over-year increase in net profit and a 4.4% growth in adjusted EBITDA for the first nine months of the year, supported by robust cash flow of $15 billion [7]. - Iberdrola offers a solid dividend yield of 3.40%, making it an attractive option for investors seeking stability and gradual growth [8]. Group 4: Vertex Pharmaceuticals (VRTX.US) - Vertex Pharmaceuticals is a biotechnology company known for its leadership in cystic fibrosis and sickle cell disease, providing strong recurring revenue and industry-leading profit growth [9]. - The company has a low price-to-earnings growth (PEG) ratio of 0.16, indicating an attractive valuation relative to its future earnings growth [9]. - Vertex is diversifying its pipeline beyond cystic fibrosis, which supports its strong forward growth indicators, including a projected EBITDA growth rate of nearly 12% [10]. Group 5: Incyte (INCY.US) - Incyte focuses on oncology and inflammatory diseases, with its flagship product Jakafi being a cornerstone of its revenue and cash flow [11]. - The company has a price-to-earnings ratio of 14.20, significantly lower than the industry median, and a PEG ratio of 0.07, indicating strong growth potential at an attractive valuation [11]. - Incyte's recent approval of a treatment option for certain adult follicular lymphomas further supports its growth outlook [11]. Summary - As the technology sector shows signs of fatigue, investors may find better risk-adjusted opportunities in defensive sectors with inherent growth drivers. Brookfield Infrastructure and Iberdrola provide classic, cash flow-driven utility defensive attributes, while Vertex Pharmaceuticals and Incyte enhance the resilience of the healthcare sector [12].

Core Viewpoint - Incyte Corporation has shown strong performance in its recent earnings report, with significant growth in revenues and earnings per share, driven by the success of its key products, particularly Jakafi and Opzelura, leading to a positive outlook for the stock [2][3][4]. Financial Performance - Incyte reported Q3 2025 adjusted earnings of $2.26 per share, exceeding the Zacks Consensus Estimate of $1.66, and up from $1.07 per share in the same quarter last year [2]. - Total revenues for Q3 2025 reached $1.37 billion, reflecting a 20% year-over-year increase, surpassing the Zacks Consensus Estimate of $1.26 billion [3]. Product Sales Breakdown - Jakafi sales amounted to $791.1 million, a 7% increase year-over-year, driven by a 10% rise in paid demand, beating the Zacks Consensus Estimate of $770 million [4]. - Opzelura generated $188 million in sales, up 35% year-over-year, exceeding the Zacks Consensus Estimate of $179.1 million, attributed to increased patient demand [5]. - Zynyz, a newly approved drug, recorded sales of $22.7 million, significantly higher than the Zacks Consensus Estimate of $9.5 million [6]. - Iclusig sales were $37.6 million, up 26% year-over-year, surpassing the Zacks Consensus Estimate of $30.6 million [7]. - Pemazyre generated $22.7 million in sales, reflecting a 10% year-over-year increase, beating the Zacks Consensus Estimate of $22 million [7]. - Minjuvi's revenues totaled $42 million, a 34% increase year-over-year, exceeding the Zacks Consensus Estimate of $37.9 million [8]. - Axatilimab-csfr (Niktimvo) recorded $45.8 million in sales, up 27% sequentially, following its launch in Q1 2025 [9]. - Jakavi royalty revenues from Novartis rose 9% to $125.6 million, beating the Zacks Consensus Estimate of $119.2 million [10]. Expenses and Cash Position - Adjusted R&D expenses totaled $467 million, down 11% year-over-year, primarily due to a prior milestone payment [14]. - Adjusted SG&A expenses were $308 million, up 11% year-over-year, driven by increased international marketing activities [15]. - As of September 30, 2025, Incyte's cash, cash equivalents, and marketable securities amounted to $2.9 billion, up from $2.4 billion as of June 30, 2025 [15]. Market Outlook - Estimates for Incyte have trended upward, with a consensus estimate shift of 9.57% in the past month [16]. - Incyte holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [18].

Core Insights - Incyte Corporation reported third-quarter 2025 adjusted earnings of $2.26 per share, exceeding the Zacks Consensus Estimate of $1.66 and more than doubling from $1.07 per share in the same quarter last year [1][9] - Total revenues for the third quarter reached $1.37 billion, reflecting a 20% year-over-year growth, driven by strong performance from Jakafi and Opzelura, and surpassing the Zacks Consensus Estimate of $1.26 billion [2][9] Revenue Breakdown - Jakafi sales amounted to $791.1 million, a 7% increase year-over-year, attributed to a 10% rise in paid demand, beating the Zacks Consensus Estimate of $770 million [3][9] - Opzelura cream generated $188 million in sales, up 35% year-over-year, driven by increased patient demand, exceeding the Zacks Consensus Estimate of $179.1 million [4][9] - Newly approved Zynyz generated $22.7 million in sales, significantly higher than the year-ago quarter and beating the Zacks Consensus Estimate of $9.5 million [5][9] - Minjuvi's revenues totaled $42 million, a 34% year-over-year increase, surpassing the Zacks Consensus Estimate of $37.9 million [6][9] - Niktimvo recorded $45.8 million in sales, up 27% sequentially, following its launch in the U.S. [7][9] Market Performance - Incyte's shares have increased by 34.8% year-to-date, outperforming the industry growth of 10.3% [8] Financial Guidance - The company revised its 2025 guidance for Jakafi revenues to a range of $3.05-$3.075 billion, up from the previous range of $3-$3.05 billion, while maintaining the guidance for Opzelura revenues at $630-$670 million [16]

Core Viewpoint - Incyte Corporation (INCY) is expected to exceed expectations in its third-quarter 2025 earnings report, with revenue estimates at $1.26 billion and earnings at $1.66 per share [1]. Group 1: Revenue Drivers - Incyte's primary revenue source is from Jakafi (ruxolitinib) sales in the U.S., with strong sales momentum anticipated across all approved indications [2][5]. - The Zacks Consensus Estimate for Jakafi's third-quarter sales is projected at $770 million, with higher royalties expected from Novartis due to increased Jakavi sales outside the U.S. [3][5]. - Additional revenue contributions are expected from Opzelura, with a sales estimate of $179.1 million, and from other drugs like Minjuvi, Pemazyre, and Iclusig, with respective sales estimates of $37.9 million, $22 million, and $30.6 million [7][10]. Group 2: Recent Developments - Incyte's recent approvals, including Niktimvo and Monjuvi's expanded use, are likely to enhance product sales [5][9]. - The company has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, which is expected to boost sales following FDA approval for a new cancer indication [9]. Group 3: Financial Performance - Year-to-date, Incyte's shares have increased by 29.3%, outperforming the industry growth of 9.3% [4]. - Incyte has a mixed earnings surprise history, with two earnings beats and two misses in the last four quarters, averaging a surprise of 4.2% [15]. Group 4: Earnings Expectations - The Earnings ESP for Incyte is +3.48%, indicating a potential earnings beat, with the most accurate estimate at $1.72 compared to the consensus estimate of $1.66 [17].

Core Insights - Incyte Corporation reported strong second-quarter 2025 results, with adjusted earnings of $1.57 per share, surpassing the Zacks Consensus Estimate of $1.39, and a significant improvement from an adjusted loss of $1.82 per share in the same quarter last year [2][10] Financial Performance - Total revenues for the second quarter reached $1.22 billion, reflecting a 16% year-over-year growth, driven by the performance of Jakafi and Opzelura, and exceeding the Zacks Consensus Estimate of $1.15 billion [3][10] - Jakafi sales amounted to $763.8 million, an 8% increase from the previous year, beating the Zacks Consensus Estimate of $744.1 million [4][10] - Opzelura cream generated $164.5 million in sales, a 35% year-over-year increase, surpassing the Zacks Consensus Estimate of $148.6 million [5][10] - Newly approved Zynyz generated $8.9 million in sales, significantly up from the previous year and exceeding the Zacks Consensus Estimate of $2.7 million [6] - Iclusig sales were $32.7 million, up 22% year over year, beating the Zacks Consensus Estimate of $29 million [6] - Pemazyre sales reached $22.2 million, reflecting a 9% increase and surpassing the Zacks Consensus Estimate of $20.2 million [6] - Minjuvi's revenues were $31.1 million, flat year over year, missing the Zacks Consensus Estimate of $34.3 million [7] - Axatilimab-csfr (Niktimvo) recorded $36.2 million in sales in its second quarter post-launch [8] Guidance and Future Outlook - The company raised its 2025 guidance for Jakafi revenues to a range of $3-$3.05 billion, up from the previous estimate of $2.95-$3 billion, while maintaining Opzelura's guidance at $630-$670 million [10][18] - Adjusted R&D expenses are now expected to be between $1.82-$1.84 billion, an increase from the prior guidance of $1.78-$1.81 billion [18] - Adjusted SG&A expenses are projected to be in the range of $1.16-$1.19 billion [18] Market Performance - Incyte's shares have increased by 1.6% year to date, outperforming the industry growth of 0.6% [9]

Core Viewpoint - Incyte Corporation reported strong first-quarter 2025 results, with adjusted earnings and revenues exceeding expectations, driven by the performance of its lead drug Jakafi and the launch of Opzelura [1][3][4]. Financial Performance - Adjusted earnings per share for Q1 2025 were $1.16, surpassing the Zacks Consensus Estimate of $1.01 and up from 58 cents in the same quarter last year [1]. - Total revenues reached $1.05 billion, a 20% increase year over year, exceeding the Zacks Consensus Estimate of $1 billion [1]. - Jakafi generated revenues of $709.4 million, a 24% increase from the previous year, driven by a 10% rise in paid demand, and also beating the Zacks Consensus Estimate of $661.1 million [3]. - Opzelura cream sales were $118.7 million, up 38% year over year, although it fell short of the Zacks Consensus Estimate of $127 million [4]. - Newly approved Zynyz generated $3 million in sales, significantly up from the previous year and exceeding the Zacks Consensus Estimate of $1.9 million [5]. Product Performance - Iclusig net product revenues were $29.5 million, down 3% year over year but above the Zacks Consensus Estimate of $28.7 million [5]. - Pemazyre sales were $18.4 million, reflecting a 4% year-over-year increase but missing the Zacks Consensus Estimate of $21.6 million [5]. - Minjuvi revenues totaled $29.6 million, a 24% increase year over year, but below the Zacks Consensus Estimate of $33.4 million [6]. - Axatilimab-csfr (Niktimvo) recorded $13.6 million in sales following its launch in Q1 2025 [7]. Guidance and Future Outlook - The company raised its 2025 Jakafi revenue guidance to a range of $2.95-$3 billion, up from the previous range of $2.93-$2.98 billion [15]. - Opzelura net product revenues are expected to be between $630-$670 million in 2025 [15]. - Adjusted research and development expenses are projected to be in the range of $1.78-$1.81 billion, while adjusted selling, general and administrative expenses are expected to be between $1.16-$1.19 billion [16]. Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $2.4 billion, an increase from $2.2 billion as of December 31, 2024 [13].